These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17106275)

  • 1. Dose-ranging phase 1 study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers.
    Jespers VA; Van Roey JM; Beets GI; Buvé AM
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):154-8. PubMed ID: 17106275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM; Coplan P; van de Wijgert JH; Kapiga SH; von Mollendorf C; Geubbels E; Vyankandondera J; Rees HV; Masenga G; Kiwelu I; Moyes J; Smythe SC
    AIDS; 2009 Jul; 23(12):1531-8. PubMed ID: 19550287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of 2 dapivirine vaginal microbicide gels and their safety vs. Hydroxyethyl cellulose-based universal placebo gel.
    Nel AM; Smythe SC; Habibi S; Kaptur PE; Romano JW
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):161-9. PubMed ID: 20574411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.
    Mayer KH; Maslankowski LA; Gai F; El-Sadr WM; Justman J; Kwiecien A; Mâsse B; Eshleman SH; Hendrix C; Morrow K; Rooney JF; Soto-Torres L;
    AIDS; 2006 Feb; 20(4):543-51. PubMed ID: 16470118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 1 Trial to Assess the Safety, Acceptability, Pharmacokinetics, and Pharmacodynamics of a Novel Dapivirine Vaginal Film.
    Bunge KE; Dezzutti CS; Rohan LC; Hendrix CW; Marzinke MA; Richardson-Harman N; Moncla BJ; Devlin B; Meyn LA; Spiegel HM; Hillier SL
    J Acquir Immune Defic Syndr; 2016 Apr; 71(5):498-505. PubMed ID: 26565716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings.
    Malcolm RK; Woolfson AD; Toner CF; Morrow RJ; McCullagh SD
    J Antimicrob Chemother; 2005 Nov; 56(5):954-6. PubMed ID: 16155060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Dapivirine Vaginal Gel and Film Formulation Pharmacokinetics and Pharmacodynamics (FAME 02B).
    Robinson JA; Marzinke MA; Bakshi RP; Fuchs EJ; Radebaugh CL; Aung W; Spiegel HM; Coleman JS; Rohan LC; Hendrix CW
    AIDS Res Hum Retroviruses; 2017 Apr; 33(4):339-346. PubMed ID: 27809557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women.
    El-Sadr WM; Mayer KH; Maslankowski L; Hoesley C; Justman J; Gai F; Mauck C; Absalon J; Morrow K; Mâsse B; Soto-Torres L; Kwiecien A
    AIDS; 2006 May; 20(8):1109-16. PubMed ID: 16691061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring.
    Romano J; Variano B; Coplan P; Van Roey J; Douville K; Rosenberg Z; Temmerman M; Verstraelen H; Van Bortel L; Weyers S; Mitchnick M
    AIDS Res Hum Retroviruses; 2009 May; 25(5):483-8. PubMed ID: 19388819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A safety and pharmacokinetic trial assessing delivery of dapivirine from a vaginal ring in healthy women.
    Nel A; Haazen W; Nuttall J; Romano J; Rosenberg Z; van Niekerk N
    AIDS; 2014 Jun; 28(10):1479-87. PubMed ID: 24901365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled Phase II extended safety study of two Invisible Condom formulations in Cameroonian women.
    Mbopi-Keou FX; Trottier S; Omar RF; Nkele NN; Fokoua S; Mbu ER; Domingo MC; Giguère JF; Piret J; Mwatha A; Mâsse B; Bergeron MG
    Contraception; 2010 Jan; 81(1):79-85. PubMed ID: 20004278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brief Report: Phase IIa Safety Study of a Vaginal Ring Containing Dapivirine in Adolescent Young Women.
    Bunge KE; Levy L; Szydlo DW; Zhang J; Gaur AH; Reirden D; Mayer KH; Futterman D; Hoesley C; Hillier SL; Marzinke MA; Hendrix CW; Gorbach PM; Wilson CM; Soto-Torres L; Kapogiannis B; Nel A; Squires KE;
    J Acquir Immune Defic Syndr; 2020 Feb; 83(2):135-139. PubMed ID: 31929401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2a Safety, Pharmacokinetics, and Acceptability of Dapivirine Vaginal Rings in US Postmenopausal Women.
    Chen BA; Zhang J; Gundacker HM; Hendrix CW; Hoesley CJ; Salata RA; Dezzutti CS; van der Straten A; Hall WB; Jacobson CE; Johnson S; McGowan I; Nel AM; Soto-Torres L; Marzinke MA;
    Clin Infect Dis; 2019 Mar; 68(7):1144-1151. PubMed ID: 30289485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.
    O'Loughlin J; Millwood IY; McDonald HM; Price CF; Kaldor JM; Paull JR
    Sex Transm Dis; 2010 Feb; 37(2):100-4. PubMed ID: 19823111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of vaginal transmission of HIV-1 in hu-SCID mice by the non-nucleoside reverse transcriptase inhibitor TMC120 in a gel formulation.
    Di Fabio S; Van Roey J; Giannini G; van den Mooter G; Spada M; Binelli A; Pirillo MF; Germinario E; Belardelli F; de Bethune MP; Vella S
    AIDS; 2003 Jul; 17(11):1597-604. PubMed ID: 12853741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women.
    Nel AM; Coplan P; Smythe SC; McCord K; Mitchnick M; Kaptur PE; Romano J
    AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1181-90. PubMed ID: 20854207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
    Goebel F; Yakovlev A; Pozniak AL; Vinogradova E; Boogaerts G; Hoetelmans R; de Béthune MP; Peeters M; Woodfall B
    AIDS; 2006 Aug; 20(13):1721-6. PubMed ID: 16931936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety, persistence, and acceptability of an antiretroviral microbicide candidate UC781.
    Bunge K; Macio I; Meyn L; Noguchi L; Parniak MA; Schwartz JL; Moncla B; Hillier S
    J Acquir Immune Defic Syndr; 2012 Aug; 60(4):337-43. PubMed ID: 22495787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled safety and acceptability study of two Invisible Condom formulations in women from Cameroon.
    Mbopi-Keou FX; Trottier S; Omar RF; Nkele NN; Fokoua S; Mbu ER; Giguere JF; Domingo MC; Piret J; Tsague L; Zekeng L; Mwatha A; Mâsse B; Bergeron MG
    Contraception; 2009 Nov; 80(5):484-92. PubMed ID: 19835725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection.
    Van Damme L; Niruthisard S; Atisook R; Boer K; Dally L; Laga M; Lange JM; Karam M; Perriens JH
    AIDS; 1998 Mar; 12(4):433-7. PubMed ID: 9520174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.